Vericel (VCEL) Accumulated Expenses (2010 - 2026)
Vericel (VCEL) posted Accumulated Expenses of $17.6 million for Q2 2026, up 26.33% sequentially from $14.0 million in Q1 2026, and up 22.49% YoY from $14.4 million in Q2 2025.
Vericel (VCEL) Accumulated Expenses (2010 - 2026) Analysis & Trends
Vericel has reported Accumulated Expenses for 17 years, with the latest figure at $17.6 million in Q2 2026.
- Quarterly Accumulated Expenses rose 22.49% year-over-year to $17.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $17.6 million (up 22.49% YoY) and the FY2025 annual result came in at $19.2 million, up 12.72% from the prior year.
- Accumulated Expenses improved to $17.6 million in Q2 2026 per VCEL's latest filing, from $14.0 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $19.2 million in Q4 2025 and troughed at $10.8 million in Q1 2022.
- A 5-year average of $14.4 million and a median of $14.0 million in 2023 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2022 and 2024: Accumulated Expenses advanced 27.59% in 2022, then declined 15.9% in 2024.
- Over 5 years, Accumulated Expenses stood at $16.2 million in 2022, then rose by 6.33% to $17.2 million in 2023, then declined by 0.87% to $17.1 million in 2024, then gained by 12.72% to $19.2 million in 2025, then slipped by 8.28% to $17.6 million in 2026.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $17.6 million, $14.0 million, and $19.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Vericel | 2.26 Bn | 2.10 Bn | 56.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17.64 Mn |
| Mar 31, 2026 | 13.97 Mn |
| Dec 31, 2025 | 19.24 Mn |
| Sep 30, 2025 | 16.29 Mn |
| Jun 30, 2025 | 14.40 Mn |
| Mar 31, 2025 | 11.42 Mn |
| Dec 31, 2024 | 17.07 Mn |
| Sep 30, 2024 | 14.34 Mn |
| Jun 30, 2024 | 12.86 Mn |
| Mar 31, 2024 | 11.03 Mn |
| Dec 31, 2023 | 17.22 Mn |
| Sep 30, 2023 | 13.63 Mn |
| Jun 30, 2023 | 13.97 Mn |
| Mar 31, 2023 | 13.11 Mn |
| Dec 31, 2022 | 16.19 Mn |
| Sep 30, 2022 | 13.95 Mn |
| Jun 30, 2022 | 12.13 Mn |
| Mar 31, 2022 | 10.79 Mn |
| Dec 31, 2021 | 14.05 Mn |
| Sep 30, 2021 | 10.93 Mn |